Postmarketing Requirement vs. Postmarketing Commitment

An NDA or BLA approval letter can list a postmarketing requirement and a postmarketing commitment on the same page, in the same format, as though they were the same kind of obligation. They are not. One is a study the sponsor is legally required to run. The other is a study the sponsor agreed, in writing, to run — and FDA cannot enforce it the same way if the sponsor’s priorities later change. Reading an approval letter well means telling the two apart on sight, not assuming the word “commitment” is doing any softening.

In brief

A postmarketing requirement (PMR) is a study or clinical trial a sponsor is required by statute or regulation to conduct after approval. A postmarketing commitment (PMC) is the same kind of study, agreed to in writing, that is not legally required.
The FDA Amendments Act of 2007 added FDCA § 505(o)(3), giving FDA explicit authority to require a postapproval study to assess a known serious risk, a signal of a serious risk, or an unexpected serious risk — the main statutory source of safety PMRs.
Missing a PMR status-report deadline without FDA-accepted “good cause” is itself a violation under § 505(o)(3)(E)(ii) — treated as misbranding under FDCA § 502(z), with civil monetary penalties available under § 303(f)(4). A missed PMC deadline carries no equivalent legal consequence.
Sponsors report PMR and PMC status annually under 21 CFR § 314.81(b)(2), and FDA’s own PMR/PMC public search tool is refreshed quarterly — so a sponsor’s status on either kind of study is public record, not an internal matter.

What the label is actually telling you

The distinction sounds bureaucratic until you remember that, before 2007, FDA used “postmarketing commitment” for both kinds of study — the mandatory ones and the voluntary ones alike. That blurred label made it hard to tell, from outside the agency, which postapproval promises a sponsor could walk away from and which ones it legally could not. FDA now keeps the terms apart on purpose: a requirement exists because a statute or regulation says the study must happen, independent of whether the sponsor thinks it is a good idea. A commitment exists because the sponsor offered it, usually during review, often to resolve a question FDA raised without turning it into a formal condition of approval. The deliverable can look identical on paper — same protocol format, same FDA-assigned tracking number, same place in the annual status report — which is exactly why the label, not the study design, is what you need to check first.

Why the split has teeth on one side and not the other

FDAAA’s § 505(o)(3) is where most safety-focused PMRs come from. It lets FDA require a postapproval study or clinical trial specifically to assess a known serious risk, assess signals of a serious risk, or identify an unexpected serious risk tied to the drug — and once FDA imposes one, the sponsor owes FDA a timetable and periodic status updates on it, not just the eventual results. Missing one of those status-report deadlines without a good-cause explanation FDA accepts is a violation of § 505(o)(3)(E)(ii) in its own right, separate from whatever is actually happening with the underlying study. That violation makes the drug misbranded under § 502(z), which opens the door to civil monetary penalties under § 303(f)(4) — real money, assessed per violation, with higher exposure if the noncompliance continues. A PMC has no equivalent provision behind it. If a sponsor lets a postmarketing commitment slip, FDA can note it publicly in the sponsor’s annual status report and in the agency’s own backlog notices, and that visibility is not nothing — but there is no misbranding charge and no civil penalty waiting behind an unmet PMC the way there is for an unexcused PMR miss.

Where this goes wrong

Assuming “commitment” means optional in any everyday sense

FDA cannot enforce a PMC the way it enforces a PMR, but a sponsor that quietly drops a study it promised in writing is building a track record that shows up in the same public status reports as everyone else’s.

Treating every postapproval study as a PMR

Plenty of postapproval studies on the books are PMCs, offered rather than mandated. Reading a commitment as though it carries statutory force overstates FDA’s actual leverage — and can lead a team to over-promise on a timeline nobody is legally holding them to.

Missing the status-report deadline instead of the study itself

The enforceable failure under § 505(o)(3)(E)(ii) is not finishing the study late — it is not reporting the delay and requesting good cause on schedule. A study genuinely behind is a very different conversation with FDA than one FDA finds out about from a missed status report.

Checking which label is attached to a given postapproval study takes one look at the approval letter or the annual status report, but it changes how seriously that study should be treated in any internal conversation about risk or priority. The same approval letter that lists PMRs and PMCs side by side is worth reading closely for everything else it commits the sponsor to. A REMS is a different postmarket safety tool again, built on its own legal basis rather than § 505(o)(3) — worth knowing apart from both.

Sources & further reading

eCFR — 21 CFR § 314.81, Other postmarketing reports ecfr.gov
Cornell LII — 21 U.S.C. § 355(o), Section 505(o) of the FD&C Act (postapproval studies and clinical trials) law.cornell.edu
FDA — Postmarketing Requirements and Commitments: Introduction fda.gov
Regulatory Academy — How to Read an FDA Drug Approval Letter regulatoryacademy.com
Regulatory Academy — How to Read a REMS regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.